Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group

TO Nielsen, SCY Leung, DL Rimm… - JNCI: Journal of the …, 2021 - academic.oup.com
Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in
breast cancer, has limited value for treatment decisions due to questionable analytical …

[HTML][HTML] miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis

CE Condrat, DC Thompson, MG Barbu, OL Bugnar… - Cells, 2020 - mdpi.com
MicroRNAs (miRNAs) represent a class of small, non-coding RNAs with the main roles of
regulating mRNA through its degradation and adjusting protein levels. In recent years …

[HTML][HTML] 21-gene assay to inform chemotherapy benefit in node-positive breast cancer

K Kalinsky, WE Barlow, JR Gralow… - … England Journal of …, 2021 - Mass Medical Soc
Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …

Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update

F Andre, N Ismaila, KH Allison, WE Barlow… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To update recommendations on appropriate use of breast cancer biomarker
assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast …

Breast cancer: Biology, biomarkers, and treatments

K Barzaman, J Karami, Z Zarei, A Hosseinzadeh… - International …, 2020 - Elsevier
During the past recent years, various therapies emerged in the era of breast cancer. Breast
cancer is a heterogeneous disease in which genetic and environmental factors are involved …

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F Cardoso, S Kyriakides, S Ohno… - Annals of …, 2019 - annalsofoncology.org
In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …

Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update

KH Allison, MEH Hammond, M Dowsett… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To update key recommendations of the American Society of Clinical
Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) …

Breast cancer treatment: a review

AG Waks, EP Winer - Jama, 2019 - jamanetwork.com
Importance Breast cancer will be diagnosed in 12% of women in the United States over the
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …

[HTML][HTML] 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

H Pan, R Gray, J Braybrooke, C Davies… - … England Journal of …, 2017 - Mass Medical Soc
Background The administration of endocrine therapy for 5 years substantially reduces
recurrence rates during and after treatment in women with early-stage, estrogen-receptor …

[HTML][HTML] Awareness and current knowledge of breast cancer

M Akram, M Iqbal, M Daniyal, AU Khan - Biological research, 2017 - Springer
Breast cancer remains a worldwide public health dilemma and is currently the most common
tumour in the globe. Awareness of breast cancer, public attentiveness, and advancement in …